Science Advances

Supplementary Materials

This PDF file includes:

  • Supplementary Materials and Methods
  • fig. S1. The expression patterns of MANF and GFP 2 weeks after intracerebral AAV7 injection.
  • fig. S2. Postischemic AAV7-MANF injection does not affect spontaneous motor activity.
  • fig. S3. AAV7-MANF injection after ischemia does not reduce lesion size.
  • fig. S4. Analysis of anti-laminin and anti-synaptophysin immunoreactivity in the peri-infarct area.
  • fig. S5. Analysis of anti-MBP immunoreactivity in the peri-infarct area.
  • fig. S6. Analysis of anti–glial fibrillary acidic protein immunoreactivity in the peri-infarct area.
  • fig. S7. AAV7-MANF injection after ischemia results in rapid hMANF expression and enhancement of behavioral recovery.
  • fig. S8. Analysis of MBP and CD68 colocalization in the external capsule.
  • fig. S9. Analysis of immune cell number on day 14 after AAV7-MANF treatment.
  • fig. S10. qPCR analysis of alternative activation marker TGFb1 and Mrc1 (CD206) mRNA levels in the peri-infarct cortex at day 4 after ischemic injury (n = 4 to 5).
  • fig. S11. Endogenous MANF has no effect on C3, Emr1, Arg1, or Mrc1 expression in the cortex after cerebral ischemic injury.
  • table S1. Top hits from RNA sequencing analysis performed to find genes expressed differentially in the peri-infarct region of AAV7-GFP–treated (n = 3) versus AAV7-hMANF–treated (n = 3) rats.
  • References (25–30)

Download PDF

Files in this Data Supplement: